Background: Reference intervals of Liver function tests are very important for the screening, diagnosis, treatment, and monitoring of liver diseases. We aim to establish common reference intervals of liver function tests specifically for the Chinese adult population.
Methods: A total of 3210 individuals (20-79 years) were enrolled in six representative geographical regions in China. Analytes of ALT, AST, GGT, ALP, total protein, albumin and total bilirubin were measured using three analytical systems mainly used in China. The newly established reference intervals were based on the results of traceability or multiple systems, and then validated in 21 large hospitals located nationwide qualified by the National External Quality Assessment (EQA) of China.
Results: We had been established reference intervals of the seven liver function tests for the Chinese adult population and found there were apparent variances of reference values for the variables for partitioning analysis such as gender(ALT, GGT, total bilirubin), age(ALP, albumin) and region(total protein). More than 86% of the 21 laboratories passed the validation in all subgroup of reference intervals and overall about 95.3% to 98.8% of the 1220 validation results fell within the range of the new reference interval for all liver function tests. In comparison with the currently recommended reference intervals in China, the single side observed proportions of out of range of reference values from our study for most of the tests deviated significantly from the nominal 2.5% such as total bilirubin (15.2%), ALP (0.2%), albumin (0.0%). Most of reference intervals in our study were obviously different from that of other races.
Conclusion: These used reference intervals are no longer applicable for the current Chinese population. We have established common reference intervals of liver function tests that are defined specifically for Chinese population and can be universally used among EQA-approved laboratories located all over China.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772807 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0072916 | PLOS |
Unlabelled: Transparent and accurate reporting in early phase dose-finding (EPDF) clinical trials is crucial for informing subsequent larger trials. The SPIRIT statement, designed for trial protocol content, does not adequately cover the distinctive features of EPDF trials. Recent findings indicate that the protocol contents in past EPDF trials frequently lacked completeness and clarity.
View Article and Find Full Text PDFFront Nutr
January 2025
Department of Ophthalmology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
Aim: This study aimed to explore the association between the ratio of 4-pyridoxine (4-PA) to pyridoxal 5'-phosphate (PLP) (4-PA/PLP) and diabetic retinopathy (DR) and further assess the mediating effect of Endothelial Activation and Stress Index (EASIX) on the association between 4-PA/PLP and DR.
Methods: In this cross-sectional study, 1,698 patients with diabetes from the National Health and Nutrition Examination Survey were included. According to the median, 4-PA/PLP was categorized into a high-level group (≥0.
IJID Reg
March 2025
Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Objectives: This study aimed to estimate the incidence of norovirus (NoV)-associated diarrhea and asymptomatic infections in children under 4 years of age and identify the genotypes of multiple NoV infections.
Methods: A community-based cohort study was conducted in Tarlac, Philippines. Children aged 0-2 years were followed up for 2 years.
Stat Biopharm Res
July 2024
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Conventionally, dose finding trials are based on dose-limiting toxicity (DLT) that only captures the most severe toxicities, e.g., treatment related grade 3 or higher toxicity according to the NCI Common Terminology Criteria for Adverse Events.
View Article and Find Full Text PDFPostepy Dermatol Alergol
December 2024
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
Introduction: Assessing the quality of life (QoL) in patients with various diseases is essential for understanding their well-being and guiding clinical management. Dermatological conditions, particularly those affecting the scalp, significantly impact QoL due to their visible nature, which can affect appearance and social interactions. While general QoL instruments like the Dermatology Life Quality Index (DLQI) exist, disease-specific tools like SCALPDEX are necessary for capturing the unique challenges faced by patients with scalp disorders.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!